Effect of oral contraceptive with and without associated estriol on ultrasound measurements of breast fibroadenoma: Randomized clinical trial

Sao Paulo Medical Journal

Volumn 125, Issue 5, 2007, Pages 275-280

  Estevão, Rodrigo Augusto Fernandes ^a,b   Nazário, Afonso Celso Pinto ^a   Baracat, Edmund Chada ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Contraceptives, oral; Estriol; Fibroadenoma; Growth substances; Ultrasonics

Indexed keywords

CONTRACEPTIVE AGENT; ESTRIOL PLUS ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; BREAST BIOPSY; BREAST FIBROADENOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ECHOMAMMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MULTIPLE CYCLE TREATMENT; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THREE DIMENSIONAL IMAGING; TUMOR VOLUME;

EID: 38049098430     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802007000500005     Document Type: Article

References (35)

1. Dent DM, Cant PJ. Fibroadenoma. World J Surg. 1989;13(6):706-10.
2. Alle KM, Moss J, Venegas RJ, Khalkhali I, Klein SR. Conservative management of fibroadenoma of the breast. Br J Surg. 1996;83(7):992-3.
3. Greenberg R, Skornick Y, Kaplan O. Management of breast fibroadenomas. J Gen Intern Med. 1998;13(9):640-5.
4. Funderburk WW, Rosero E, Leffall LD. Breast lesions in blacks. Surg Gynecol Obstet. 1972;135(1):58-60.
5. Nigro DM, Organ CH Jr. Fibroadenoma of the female breast. Some epidemiologic surprises. Postgrad Med. 1976;59(5):113-7.
6. Barrow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Caancer. 1987;60(11):2751-60.
7. Haagensen CD. Diseases of the breast. 3rd. Philadelphia: WB Saunders; 1986.
8. Carty NJ, Carter C, Rubin C, Ravichandran D, Royle GT, Taylor I. Management of fibroadenoma of the breast. Ann R Coll Surg Engl. 1995;77(2):127-30.
9. Wilkinson S, Anderson TJ, Rifkind E, Chetty, U, Forrest, AP. Fibroadenoma of the breast: a follow-up of conservative management. Br J Surg. 1989;76(4):390-1.
10. Sitruk-ware LR, Sterkers N, Mowszowicz I, Mauvais-Jarvis P. Inadequate corpus luteal function in women with benign breast diseases. J Clin Endocrinol Metab. 1977;44(4):771-4.
11. Monterrosa Castro A. Actualización de conceptos en anticonceptivos orales combinados [monograph online). 2nd. Colombia; 2000. Available from: http://encolombia.com/anticonceptivos1.htm. Accessed in 2007 (Aug 14).
12. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29-38.
13. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc (Wash). 2001;41(6):875-86, quiz 925-6.
14. Mishell DR Jr, Kletzky OA, Brenner PF, Roy S, Nicoloff J. The effect of contraceptive steroids on hypothalamic-pituitary function. Am J Obster Gynecol. 1977;128(1):60-74.
15. Cohen BL, Katz M. Pituitary and ovarian function in women receiving hormonal contraception. Contraception. 1979;20(5):475-87.
16. Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol. 1994;170(5 Pt 2):1499-507.
17. Ravnihar B, Siegel DG, Lindtner J. An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Eur J Cancer 1979;15(4):395-405.
18. Sitruk-Ware R, Thalabard JC, Benotmane A, Mauvais-Jarvis P. Risk factors for breast fibroadenoma in young women. Contraceptive l989;40(3):251-68.
19. Speroff L, Glass RH, Kase NG. Endocrinologia ginecológica clínica e infertilidade. 5th ed. São Paulo: Manole; 1995.
20. Neter J, Wasserman W, Kutner MH. Applied linear statistical models. 3rd ed. New York: Irwin Inc; 1990.
21. Conover WJ. Practical nonparametric statistics. 2nd Edition. New York: John & Sons; 1980.
22. Zamith R, Lima GR. Contracepção na adolescência. In: Lima GR. Girão MJBC, Baracat EC, editors. Ginecologia de consultório. São Paul: EPM - Editora de Projetos Médicos; 2003, p 147-56.
23. Epithelial ovarian cancer and combined oral contraceptive. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 1989;18(3):538-45.
24. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987;257(6):796-800.
25. Leonardi M. Contraccezione ormonale e patologia mammaria benigna. Valutazione di un protocollo di trattamento nella mastopatia cronica con mastalgia- [Hormonal contraception and benign breast disease. Evaluation of a treatment protocol for chronic mastoparthy with mastalgial. Minerva Ginecol. 1997;49(6):271-6.
26. Brinton LA, Vessey MP, Flavel R, Yeates D. Risk factors for benign breast disease. Am J Epidemiol. 1981;113(3):203-14.
27. Sawhney N, Garrahan N, Douglas-Jones AG, Williams ED. Epithelial-stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer. 1992;70(8):2115-20.
28. Hasebe T, Imoto S, Sasaki S, Tsubono Y, Mukai K. Proliferative activity and tumor angiogenesis is closely correlated to stromal cellularity of fibroadenoma: proposal fibroadenoma, cellular variant. Pathol Int. 1999;49(5):435-43.
29. Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer. 1997;70(6):639-43.
30. Kuijper A. Buerger H, Simon R, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol. 2002;197(5):575-81.
31. Canny PF, Berkowitz GS, Kelley JL, LiVolsi VA. Fibroadenoma and the use of exogenous hormones. A case-control study. Am J Epidemiol. 1988;127(3):454-61.
32. Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast. Int J Cancer. 1999;82(2):191-6.
33. Yu H, Rohan TE, Cook MG, Howe GR, Miller AB. Risk factors for fibroadenoma: cause-control study in Australia. Am J Epidemiol. 1992;135(3):247-58.
34. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. Goodman and Gilman's: the pharmacological basis of therapeutics. 9th ed, New York: McGraw Hill; 1996.
35. Umekita Y, Yoshida H. Immunohistochemical study of MIB1 expression in phyllodes tumor and fibroadenoma. Pathol Int. 1999;49(9):807-10.